MPL and Thrombocytopenia: Thrombopoietin receptor (TPO-R) agonists, lusutrombopag or avatrombopag, are approved for regulatory agencies in ACLD patients undergoing invasive procedures with severe thrombocytopenia (platelet count < 50,000/uL).